Phase 1 study of tumor-infiltrating lymphocytes (TIL) in patients with pancreatic cancer
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Tumour infiltrating lymphocytes (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 04 Nov 2016 According to Lion Biotechnologies media release, this trial is expected to begin in 2017.
- 05 Oct 2016 New trial record